Director Gilbert A Fuller completed a sale of 1,058 shares of common stock in USANA Health Sciences Inc (NASDAQ: USNA) on March 20, 2026. The shares changed hands at $17.0 per share, producing a total transaction value of $17986. Following the disposition, Fuller directly holds 0 shares of USANA.
This insider sale coincides with USANA trading close to its 52-week low of $16.71. The company’s share price is down 42% over the past six months, according to the figures provided. An InvestingPro analysis cited by the company indicates the stock appears undervalued at current prices and places USANA on that platform’s list of most undervalued stocks. Investors can obtain further analysis through a Pro Research Report available for this company and more than 1,400 other U.S. equities.
Separately, USANA updated its financial outlook for the near term. The company now anticipates net sales for fiscal year 2025 to be approximately $925 million, a modest increase from prior guidance of $920 million. For fiscal 2026, USANA issued an initial sales forecast projecting revenue in a range between $925 million and $1 billion.
Within that 2026 outlook, USANA expects sales from its core nutritional business to decline, with estimates between $720 million and $765 million. That range represents a drop from an approximate $777 million in core nutritional sales in 2025. The company released these projections ahead of its scheduled presentation at the ICR Conference.
The combination of an insider sale, a share price trading near its yearly low, and updated sales guidance frames the current market snapshot for USANA. The company’s small upward revision to 2025 net sales guidance is paired with a more cautious initial estimate for 2026 overall revenue and an explicit expectation of lower sales within the core nutritional segment.
Context and next steps
Market participants looking for more detailed analysis can consult the referenced Pro Research Report for USANA, which is listed among over 1,400 U.S. equities covered on the platform noted in company materials. The firm’s presentation at the ICR Conference will follow the release of these projections.